Brief: Cytomx Announces Positive Interim Data From Phase 1 Dose Escalation Study Of Epcam Antibody Drug Conjugate (Cx-2051) Candidate In Patients With Advanced Colorectal Cancer (Crc)
12/05/2025 12:27
May 12 (Reuters) - CytomX Therapeutics Inc CTMX.O: CYTOMX ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 1 DOSE ESCALATION STUDY OF EPCAM ANTIBODY DRUG CONJUGATE (CX-2051) CANDIDATE IN PATIENTS WITH ADVANCED COLORECTAL CANCER (CRC) CYTOMX THERAPEUTICS INC - PLANNING PHASE 2 STUDY INITIATION IN 1H 2026 CYTOMX THERAPEUTICS INC - CX-2051 HAS BEEN GENERALLY WELL TOLERATED Source text: ID:nGNX4Kb8r7 Further company coverage: CTMX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CytomX Therapeutics
See all newsCytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration
CytomX Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Cytomx Therapeutics Announces Appointment Of Charles Fuchs, M.D., M.P.H., To The Board Of Directors
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway